
Armata Pharmaceuticals, Inc.
100
Recent developments include Armata's Q3 financial results reporting a loss but revenue exceeding expectations, FDA regulatory progress including Breakthrough Therapy Designation for AP-SA02, and advances in phage therapy research publications. The company also received funding from the Department of Defense to support Phase 3 development of AP-SA02.
- Armata Pharmaceuticals reported Q3 2026 results showing a loss but revenue above expectations [N1].
- The company received FDA Breakthrough Therapy Designation for AP-SA02 in complicated Staphylococcus aureus bacteremia [N1].
- Armata secured $3.7 million in Department of Defense funding for Phase 3 development of AP-SA02 [N1].
- Armata advanced phage therapy research with a new publication on Ar-KM [N5].
- The company obtained FDA agreement on a pediatric plan for AP-SA02 in Staphylococcus aureus bacteremia [N7].
- Armata delayed Q4 and full-year results while providing business updates in March 2026 [N8].
Armata Pharmaceuticals develops pathogen-specific bacteriophage therapies as alternatives to traditional antibiotics, focusing on antibiotic-resistant and difficult-to-treat bacterial infections. The company leverages proprietary technology to produce high-purity, high-potency phage therapeutics with consistent manufacturing processes. Its clinical pipeline includes AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa and AP-SA02 for complicated Staphylococcus aureus bacteremia. Armata has completed multiple Phase 2 clinical trials demonstrating favorable safety and bacterial load reduction. The company maintains manufacturing and research facilities in California and Australia and actively engages with regulatory authorities including the FDA. Armata's business model centers on advancing phage therapeutics through clinical development toward potential regulatory approval and commercialization, supported by grants and government funding.
Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company specializing in bacteriophage therapeutics targeting antibiotic-resistant bacterial infections. The company has advanced clinical candidates AP-PA02 and AP-SA02, with completed Phase 2 trials demonstrating safety and efficacy signals. Manufacturing capabilities support high-purity phage production. As of September 30, 2026, Armata reported $18.3 million in cash and equivalents, a current ratio of 0.12, and net income of $54.9 million for the quarter. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Recent news includes Q3 results with a loss but revenue above expectations and regulatory progress including FDA Breakthrough Therapy Designation [S2][N1][N7].
Armata's clinical progress with AP-PA02 and AP-SA02 demonstrates potential for bacteriophage therapies as alternatives to antibiotics in difficult-to-treat infections. Positive safety and efficacy signals from Phase 2 trials, combined with FDA Breakthrough Therapy Designation and government funding, support the advancement of its pipeline. Proprietary manufacturing capabilities and consistent product quality position the company to address unmet medical needs in antibiotic resistance. Strategic partnerships and further clinical development could enhance Armata's market presence in phage therapeutics.
Armata faces challenges including substantial current liabilities relative to assets, reflected in a low current ratio of 0.12 as of September 30, 2026, indicating liquidity constraints. Clinical development is contingent on securing additional funding, and regulatory approval risks remain. The niche phage therapy market is competitive and evolving, with uncertainties around commercial viability and reimbursement. Manufacturing scale-up and market adoption may encounter hurdles. Delays or negative clinical outcomes could impact business prospects.
Armata's moat derives from its proprietary bacteriophage technology platform, including expertise in identifying, characterizing, and manufacturing high-purity phage therapeutics with lot-to-lot consistency. The company's clinical-stage pipeline with multiple completed Phase 2 trials and FDA regulatory designations provides a competitive advantage in the niche of phage therapy for antibiotic-resistant infections. Manufacturing capabilities and cGMP facilities further strengthen its position by enabling scalable production. The specialized nature of phage therapeutics and regulatory progress create barriers to entry for competitors.
• Liquidity Risk: As of September 30, 2026, Armata's current liabilities significantly exceed current assets, resulting in a low current ratio of 0.12 and cash ratio of 0.1, indicating potential liquidity constraints that may affect ongoing operations and clinical development.
• Clinical Development Risk: Advancement of clinical candidates AP-PA02 and AP-SA02 depends on successful trial outcomes and securing sufficient funding. Clinical trials carry inherent risks of delays, adverse events, or failure to demonstrate efficacy.
• Regulatory Risk: Armata's therapies require regulatory approvals which involve uncertainties. Although the company has received FDA Breakthrough Therapy Designation for AP-SA02, full approval processes remain complex and uncertain.
• Market Adoption Risk: Phage therapeutics represent a novel treatment approach with uncertain market acceptance, reimbursement, and competitive dynamics that could impact commercial success.
• Operational Risk: The company relies on proprietary manufacturing processes and leased facilities. Disruptions in manufacturing, supply chain, or facility operations could adversely affect product development and commercialization.
Business trends: Continued clinical development of bacteriophage therapeutics targeting antibiotic-resistant infections with regulatory designations and government funding.
Execution milestones: Completion of Phase 3 trials for AP-SA02, potential initiation of Phase 3 for AP-PA02, and advancement of manufacturing and commercialization capabilities.
Key risks: Liquidity constraints, clinical trial outcomes, regulatory approval uncertainties, and market adoption challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company focused on developing high-purity and potency, pathogen-specific bacteriophage therapeutics targeting antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology [S1].
- The company has completed three Phase 2 clinical trials to date [S1].
- Armata's lead phage product candidates include AP-PA02 targeting Pseudomonas aeruginosa for chronic pulmonary infections and AP-SA02 targeting Staphylococcus aureus for complicated bacteremia [S1].
- AP-PA02 has completed Phase 1b/2a and Phase 2 studies in cystic fibrosis and non-cystic fibrosis bronchiectasis patients, demonstrating favorable safety, tolerability, and bacterial load reduction [S1].
- AP-SA02 completed a Phase 1b/2a study for complicated S. aureus bacteremia, showing positive topline data with good tolerability and no serious adverse events related to the drug [S1].
- The company has proprietary cGMP manufacturing capabilities enabling high titer and purity phage production with lot-to-lot consistency, supporting potential commercialization [S1].
- Armata has received FDA approvals for IND applications for AP-PA02 and AP-SA02 and has obtained FDA Breakthrough Therapy Designation for AP-SA02 in complicated S. aureus bacteremia [N1][N7].
- Armata has received funding from the Department of Defense and other grants to support Phase 3 development of AP-SA02 [N1].
- The company leases office, research, and manufacturing facilities in Los Angeles, Marina del Rey, California, and Sydney, Australia, with manufacturing capacity to support contract manufacturing opportunities [S1].
- As of September 30, 2026, Armata reported cash and cash equivalents of $18.3 million and current assets of $22.6 million, with current liabilities of $186.8 million, resulting in a current ratio of 0.12 and a cash ratio of 0.1 [S2].
- The company reported net income of $54.9 million and basic EPS of $1.15 for the quarter ended September 30, 2026, with diluted EPS of -$0.24 [S2].
- Armata's common stock trades on the NYSE American under the ticker ARMP, with approximately 37.2 million shares outstanding as of November 6, 2026 [S2].
- The company has not declared or paid dividends and intends to retain funds to support operations and growth [S1].
- Armata's board and management maintain active cybersecurity governance with oversight delegated to the Audit Committee, including risk management, incident response, and compliance programs [S1].
- Recent news highlights include Q3 financial results reporting a loss but revenue exceeding expectations, FDA agreements on pediatric plans, and advances in phage therapy research [N1][N5][N7][N8].
Generated 2026-11-13
- S1 | 2026-03-25 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/armata-pharmaceuticals-inc-armp-reports-q3-loss-beats-revenue-estimates
- N2 | 2026-11-10 | www.nasdaq.com | Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates | https://www.nasdaq.com/articles/liquidia-corporation-lqda-q3-earnings-and-revenues-beat-estimates
- N3 | 2026-11-05 | www.nasdaq.com | Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/starling-oncology-inc-stln-reports-q3-loss-beats-revenue-estimates
- N4 | 2026-11-02 | www.nasdaq.com | Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/krystal-biotech-inc-krys-surpasses-q3-earnings-and-revenue-estimates
- N5 | 2026-09-03 | www.nasdaq.com | Armata Pharmaceuticals Advances Phage Therapy Research With New Ar-KM Publication | https://www.nasdaq.com/articles/armata-pharmaceuticals-advances-phage-therapy-research-new-ar-km-publication
- N6 | 2026-07-21 | www.nasdaq.com | Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-zybt-skyrockets-advb-drops-planned-offering-stim-gets-new-cfo-rdgt
- N7 | 2026-07-13 | www.nasdaq.com | Armata Gets FDA Agreement On Pediatric Plan For AP-SA02 In SAB | https://www.nasdaq.com/articles/armata-gets-fda-agreement-pediatric-plan-ap-sa02-sab
- N8 | 2026-03-19 | www.nasdaq.com | Armata Pharmaceuticals Delays Q4 And Full-year Results; Provides Business Updates | https://www.nasdaq.com/articles/armata-pharmaceuticals-delays-q4-and-full-year-results-provides-business-updates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


